Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach
Year: 2026
Type: article
Abstract: The development of precision medicine approaches in oncology has revolutionized clinical practice. Although definitions of precision medicine may vary, it is reasonably defined as the use of biomarkers to select a treatment approach for a patient to optimize the chance of response [ 1 , 2 , 3 ]. Key examples that define current standard practice include the use of genomics to guide therapy, such as FLT3 inhibitors in Acute Myeloid Leukemia (AML) with FLT3-ITD, and the use of the Oncotype Dx assay to assess the relative risk and benefit of chemotherapy in invasive Breast Cancer [ 4 , 5 ]. The number of such precision approaches in oncology continues to rapidly expand [ 1 ].
Source: Leukemia
Authors: Raajit K. Rampal, Richard Winneker, Andrew Kuykendall, Laura C. Michaelis, Ghaith Abu-Zeinah, Steffen Koschmieder, Jan Philipp Bewersdorf, Zi Yun Ng, Gabriella Hobbs, Bridget Marcellino, Linda Resar, Joseph Scandura, Anand Patel, John Mascarenhas, Aaron Gerds, Douglas Tremblay, Shane Mayack, Andriy Derkach, Florian H. Heidel
Institutions: Memorial Sloan Kettering Cancer Center, MPN Research Foundation, Moffitt Cancer Center, Medical College of Wisconsin, Weill Cornell Medicine, Universitätsklinikum Aachen, RWTH Aachen University, Yale University, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Harvard University, Massachusetts General Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Chicago, Cleveland Clinic, Medizinische Hochschule Hannover
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Awards: G2051006376, G289723095
OpenAlex ID: W7204880422